Citations

Clear

1053 citation(s) found for "Andre, F".

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Seymour, John F. , Byrd, John C. , Munir, Talha, Kater, Arnon P. , Chanan‐Khan, Asher , Furman, Richard R. , O’Brien, Susan, Brown, Jennifer R. , Mato, Anthony R. , Fehn, Thomas, Miranda, Paulo Andre P. de, Higgins, Kara, John, Ellie , Borja, Marianne de, Woyach, Jennifer A. , Byrd, John C , Ghia, Paolo , O’Brien, Susan , Stilgenbauer, Stephan , Fehn, Thomas, Jurczak, Wojciech

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7050-7052

10.1182/blood-2022-157060 Get It

Novel Genetic Determinants of Dental Maturation in Children
Grgić, Olja, Prijatelj, Vid , Dudakovic, Amel , Vucic, S. , Dhamo, Brunilda , Monnereau, Claire , Zrimšek, Maša , Gautvik, Kaare M. , Reppe, Sjur , Shimizu, Emi , Haworth, Simon , Timpson, Nicholas J. , Uitterlinden, André G. , Ongkosuwito, Edwin M. , Wijnen, André J. van , Rivadeneira, Fernando , Wolvius, Eppo B. , Prijatelj, V , Vucic, S , Dhamo, B , Zrimsek, M , Haworth, S , van Wijnen, Andre J , Trajanoska, Katerina , Jaddoe, Vincent W. V. , Järvelin, Marjo‐Riitta , Evans, David M. , Medina‐Gómez, Carolina

Mayo Clinic

Journal of Dental Research | November 28, 2022 | Volume: 102 | Issue: 3 | Pages: 349-356

10.1177/00220345221132268 | PMID 36437532 Get It

Dental occlusion requires harmonious development of teeth, jaws, and other elements of the craniofacial complex, which are regulated by environmental and genetic factors. We performed the first genome-wide association study (GWAS) on dental development (DD) using the Demirjian radiographic method. Radiographic assessments from participants of the Generation R Study (primary study population, N 1 = 2,793; mean age of 9.8 y) were correlated with ~30 million genetic variants while adjusting for age, sex, and genomic principal components (proxy for population stratification). Variants associated with DD at genome-wide significant level ( P < 5 × 10 −8 ) mapped to 16q12.2 ( IRX5) (lead variant rs3922616, B = 0.16; P = 2.2 × 10 −8 ). We used Fisher’s combined probability tests weighted by sample size to perform a meta-analysis ( N = 14,805) combining radiographic DD at a mean age of 9.8 y from Generation R with data from a previous GWAS ( N 2 = 12,012) on number of teeth (NT) in infants used as proxy of DD at a mean age of 9.8 y (including the ALSPAC and NFBC1966). This GWAS meta-analysis revealed 3 novel loci mapping to 7p15.3 ( IGF2BP3: P = 3.2 × 10 −8 ), 14q13.3 ( PAX9: P = 1.9 × 10 −8 ), and 16q12.2 ( IRX5: P = 1.2 × 10 −9 ) and validated 8 previously reported NT loci. A polygenic allele score constructed from these 11 loci was associated with radiographic DD in an independent Generation R set of children ( N = 703; B = 0.05, P = 0.004). Furthermore, profiling of the identified genes across an atlas of murine and human stem cells observed expression in the cells involved in the formation of bone and/or dental tissues (>0.3 frequency per kilobase of transcript per million mapped reads), likely reflecting functional specialization. Our findings provide biological insight into the polygenic architecture of the pediatric dental maturation process.
Distinctive Nested Glomoid Neoplasm
Papke, David , Oliveira, André M. , Sholl, Lynette M. , Fletcher, Christopher D.�M. , Papke, David J , Dickson, Brendan C.

Mayo Clinic

American Journal of Surgical Pathology | November 17, 2022 | Volume: 47 | Issue: 1 | Pages: 12-24

10.1097/pas.0000000000001979 | PMID 36395474 Get It

Recently, it has been recognized that a subset of primary soft tissue neoplasms with GLI1 gene alterations exhibit nested architecture and can mimic glomus tumors or well-differentiated neuroendocrine tumors. Here, we report a series of 20 such neoplasms, which we have provisionally termed “distinctive nested glomoid neoplasm.” Eleven patients (55%) were female and 9 were male. The median age at presentation was 41.5 years (range: congenital to 74 y). The anatomic distribution was wide, with body sites including the trunk (7 tumors), lower extremity (5), tongue (4), upper extremity (3), and neck (1). Excluding tumors of the tongue, 10 tumors (62%) arose in deep soft tissue and 6 (38%) arose primarily in the subcutis. Tumor size ranged from 0.9 to 11.1 cm (median: 3 cm). Distinctive nested glomoid neoplasms are composed of nests of round-to-ovoid cells with scant, palely eosinophilic cytoplasm and monomorphic nuclei with vesicular chromatin and small nucleoli. The nests are invested by prominent capillary networks, and they are situated within large lobules separated by irregular, thick fibrous septa. Among 18 tumors for which adjacent non-neoplastic tissue could be assessed, perivascular proliferation of tumor cells was identified in 16 tumors (89%). Microcystic architecture was present at least focally in 8 tumors (40%), and myxoid stroma was identified at least focally in 5 (25%). Seven tumors (35%) showed clear cell features. By immunohistochemistry, some tumors expressed MDM2 (7/15; 47%), S100 (5 of 19; 26%), STAT6 (2 of 5; 20%), and AE1/AE3 (1/5; 20%). Tumors rarely expressed pan-keratin (1/10; 10%) or CAM5.2 (1/10), and all tumors were negative for β-catenin (12 tumors), chromogranin (12), synaptophysin (11), epithelial membrane antigen (10), desmin (10), smooth muscle actin (9), INSM1 (7), and CD34 (6). GLI1 break-apart fluorescence in situ hybridization was performed on 7 tumors, and next-generation sequencing was performed on 15 tumors (10 DNA sequencing only, 1 RNA sequencing only, 4 both DNA and RNA sequencing). Sixteen tumors, including all 15 tested by next-generation sequencing and an additional case tested by fluorescence in situ hybridization only, were found to harbor GLI1 gene alterations: 10 harbored GLI1 gene rearrangements (3 ACTB::GLI1, 2 PTCH1::GLI1, 1 HNRNPA1::GLI1, 1 NEAT1::GLI1, 1 TXNIP::GLI1, 2 undetermined fusion partners), and 6 harbored GLI1 amplification. Clinical follow-up was available for 10 patients (50%; range: 3 mo to 10 y; median: 6.4 y), including 8 with >1 year of follow-up. Three patients (30%) experienced local recurrence (at intervals of 3 mo to 10 y). None developed distant metastases or died of disease as yet. Overall, our findings support the notion that a subset of GLI1-altered soft tissue neoplasms are indolent, morphologically distinctive nested glomoid neoplasms that should not be classified as sarcomas.
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Ashkan, Keyoumars, Campian, Jian , Trusheim, John, Tran, David , Anstass, George, Cobbs, Charles , Heth, Jason , Salacz, Michael, D’Andre, Stacy D. , Aiken, Robert, Moshel, Yaron A., Nam, Jooyeon, Pillainayagam, Clement, Wagner, Stephanie A., Walter, Kevin A. , Chaudary, Rekha, Goldlust, Samuel , Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin O. , Mikkelsen, Tom , Walbert, Tobias , Abram, Steve, Ewend, Matthew G., Khagi, Simon , Lovick, Darren, Kim, Lyndon, Loudon, William G. , Martinez, Nina , Thompson, Reid, Avigan, David , Fink, Karen, Geoffroy, Francois J., Giglio, Pierre , Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott , Nadji‐Ohl, Minou , Sanchin, Lhagva, Sloan, Andrew, Bosch, Marnix L. , Liau, Linda M. , Brem, Steven , IWAMOTO, FABIO MASSAITI , Tran, David D. , Lee, Ian , Bota, Daniela A. , Brenner, Andrew Jacob , Portnow, Jana , Lutzky, Jose , Meisel, Hans Jörg

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii66-vii66

10.1093/neuonc/noac209.259 Get It

Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years. We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and METHODS Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo. Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo. The primary and secondary endpoints compare overall survival (OS) with contemporaneous, matched external controls. Four sets of analyses were conducted to ensure rigorous matching of the controls, reduce biases, and confirm the robustness of the results. RESULTS 331 patients were enrolled. With the crossover, 89% received murcidencel. Median OS (mOS) for nGBM patients (n = 232) was 19.3 months from randomization (22.4 months from surgery) with murcidencel vs. 16.5 months from randomization in the controls (HR = 0.80, p = 0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For rGBM (n = 64), mOS was 13.2 months from relapse vs. 7.8 months in the controls (HR = 0.58, p &lt; 0.001). Survival at 24 months post-recurrence was 20.7% vs. 9.6%, and at 30 months post-recurrence was 11.1% vs 5.1%. In nGBM patients with methylated MGMT (n = 90), mOS was 30.2 months from randomization (33 months from surgery) with murcidencel vs. 21.3 months from randomization in the controls (HR = 0.74, p = 0.027). The treatment was well tolerated, with only 5 serious adverse events deemed at least possibly related to the vaccine. CONCLUSION Clinically meaningful and statistically significant survival extension was seen in both nGBM and rGBM patients treated with murcidencel and SOC compared with contemporaneous, matched external controls who received SOC alone.
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer
Mucci, Lorelei A. , Vinson, Jacob, Gold, Theresa Margaret, Gerke, Travis , Filipenko, Julie, Green, Rebecca , Anderson, Simon , Badal, Simone , Bjartell, Anders , N., Kim , Davis, Ian D. , Enting, Deborah , Fay, André P. , Mateo, Joaquı́n , McDermott, Ray , Olmos, David , Omlin, Aurelius , Popoola, Ademola , Ragin, Camille , Roberts, Robin , Russnes, Kjell M. , Waihenya, Charles, Hyslop, Terry , Villanti, Paul , George, Daniel J. , Team, on behalf of the IRONMAN Global, Green, Rebecca M , Anderson, Simon G , Chi, Kim N , Mateo, Joaquin , McDermott, Ray , Odedina, Folakemi , Olmos, David , Omlin, Aurelius , Popoola, Ademola A , Ragin, Camille , Roberts, Robin , Stopsack, Konrad H , George, Daniel J , Lazarus, J. Michael , Stopsack, Konrad H. , Kantoff, Philip W. , Team, on behalf of the IRONMAN Global

Mayo Clinic

JCO Global Oncology | November 4, 2022 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/go.22.00154 | PMID 36332173 Get It

PURPOSE To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. PATIENTS AND METHODS Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires. RESULTS Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service. CONCLUSION To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
Gallois, Claire , Shi, Qian , Meyers, Jeffrey P., Alberts, Steven R. , Gramont, Aimery de , Sobrero, Alberto F. , Haller, Daniel G. , Oki, Eiji , Shields, Anthony F. , Goldberg, Richard M. , Lonardi, Sara , Yothers, Greg , Kelly, Caroline , Boukovinas, Ioannis , Souglakos, Ioannis , Meyerhardt, Jeffrey A. , Papamichael, Demetris , Taı̈eb, Julien , Iveson, Timothy J , Alberts, Steven R , De Gramont, Aimery , Sobrero, Alberto , Haller, Daniel , Oki, Eiji , Shields, Anthony F , Goldberg, Richard M , Lonardi, Sara , Yothers, Greg , Boukovinas, Ioannis , Sinicrope, Frank A , Yoshino, Takayuki , Meyerhardt, Jeffrey A , André, Thierry , Taieb, Julien , Shi, Qian , Iveson, Timothy , Kerr, Rachel , Labianca, Roberto , Sinicrope, Frank A. , Yoshino, Takayuki , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | November 4, 2022 | Volume: 41 | Issue: 4 | Pages: 803-815

10.1200/jco.21.02726 | PMID 36306483 Get It

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis. MATERIALS AND METHODS We studied the prognostic impact of ETD and EOD in patients with stage III CC from the ACCENT/IDEA databases, where patients were planned to receive 6 months of infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine plus oxaliplatin. ETD was defined as discontinuation of treatment and EOD as discontinuation of oxaliplatin only before patients had received a maximum of 75% of planned cycles. Association between ETD/EOD and overall survival and disease-free survival (DFS) were assessed by Cox models adjusted for established prognostic factors. RESULTS Analysis of ETD and EOD included 10,447 (20.9% with ETD) and 7,243 (18.8% with EOD) patients, respectively. Compared with patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, with Eastern Cooperative Oncology Group performance status ≥ 1, and for ETD, older with a lower body mass index. In multivariable analyses, ETD was associated with a decrease in disease-free survival and overall survival (hazard ratio [HR], 1.61, P < .001 and HR, 1.73, P < .001), which was not the case for EOD (HR, 1.07, P = .3 and HR, 1.13, P = .1). However, patients who received < 50% of the planned cycles of oxaliplatin had poorer outcomes. CONCLUSION In patients treated with 6 months of oxaliplatin-based chemotherapy for stage III CC, ETD was associated with poorer oncologic outcomes. However, this was not the case for EOD. These data favor discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.
Localized bioelectrical conduction block from radiofrequency gastric ablation persists after healing: safety and feasibility in a recovery model
Aghababaie, Zahra , O’Grady, Gregory , Nisbet, Linley A., Modesto, Andre E. , Chan, Chih-Hsiang Alexander , Matthee, Ashton , Farrugia, Gianrico , Asirvatham, Samuel J. , Cheng, Leo K. , Farrugia, Gianrico , O'Grady, Gregory , Paskaranandavadivel, Niranchan , Cheng, Leo K , Angeli-Gordon, Timothy R , Asirvatham, Samuel J , Amirapu, Satya , Beyder, Arthur , Sands, Gregory B. , Paskaranandavadivel, Niranchan , Angeli, Timothy R.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | October 18, 2022 | Volume: 323 | Issue: 6 | Pages: G640-G652

10.1152/ajpgi.00116.2022 | PMID 36255716 Get It

Ablation has recently emerged as a tool for modulating gastric electrical activation and may hold interventional potential for disorders of gastric function. However, previous studies have been limited to the acute intraoperative setting. This study now presents the safety of gastric ablation after postsurgical recovery and healing. Localized electrical conduction blocks created by ablation remained after 2 wk of healing, and no perforation or other complications were observed over the postsurgical period.
Effect of Hypoxia Preconditioning on the Regenerative Capacity of Adipose Tissue Derived Mesenchymal Stem Cells in a Model of Renal Artery Stenosis
Farooqui, Naba , Mohan, Arjunmohan , Isik, Busra , Goksu, Busra B., Thaler, Roman , Zhu, Xiang, Krier, James D., Saadiq, Ishran M. , Ferguson, Christopher M. , Jordan, Kyra L., Textor, Stephen C., Hickson, La Tonya J, Wijnen, André J. van , Lerman, Lilach O. , Eirin, Alfonso , van Wijnen, Andre J , Tang, Hui Jun , Hickson, LaTonya J. , Eirin, Alfonso , Herrmann, Sandra M.

Mayo Clinic

Stem Cells | October 17, 2022 | Volume: 41 | Issue: 1 | Pages: 50-63

10.1093/stmcls/sxac073 | PMID 36250949 Get It

Abstract Atherosclerotic renal artery stenosis (ARAS) is associated with irreversible parenchymal renal disease and regenerative stem cell therapies may improve renal outcomes. Hypoxia preconditioning (HPC) may improve the regenerative functions of adipose tissue-derived mesenchymal stem cells (AMSC) by affecting DNA 5-hydroxymethylcytosine (5hmC) marks in angiogenic genes. Here, we investigated using a porcine ARAS model, whether growth of ARAS AMSCs in hypoxia (Hx) versus normoxia (Nx) would enhance renal tissue repair, and comprehensively analyze how HPC modifies DNA hydroxymethylation compared to untreated ARAS and healthy/normal pigs (n=5 each). ARAS pigs exhibited elevated serum cholesterol, serum creatinine and renal artery stenosis, with a concomitant decrease in renal blood flow (RBF) and increased blood pressure (BP) compared to healthy pigs. Renal artery injection of either autologous Nx or Hx AMSCs improved diastolic BP, reduced kidney tissue fibrosis, and inflammation (CD3+ T-cells) in ARAS pigs. In addition, renal medullary hypoxia significantly lowered with Nx but not Hx AMSC treatment. Mechanistically, levels of epigenetic 5hmC marks (which reflect gene activation) estimated using DNA immunoprecipitation technique were elevated in profibrotic and inflammatory genes in ARAS compared with normal AMSCs. HPC significantly reduced 5hmC levels in cholesterol biosynthesis and oxidative stress response pathways in ARAS AMSCs. Thus, autologous AMSCs improve key renovascular parameters and inflammation in ARAS pigs, with HPC mitigating pathological molecular effects on inflammatory and profibrotic genes which may play a role in augmenting regenerative capacity of AMSCs.
Skull Base Registries: A Roadmap
Parikh, Kara P., Beer‐Furlan, André , Michael, L. Madison, Rangarajan, Sanjeet V., Kshettry, Varun R. , Saleh, Sara , Mukherjee, Debraj , Kirsch, Claudia , Sorenson, Jeffrey, Choby, Garret W, Saleh, Sara , Kirsch, Claudia , Mukherjee, Debraj , Parikh, Kara A. , Motiwala, Mustafa , Michael, Lattimore Madison , Choby, Garret , McKean, Erin L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 31, 2022 | Volume: 83 | Issue: 06 | Pages: 561-578

10.1055/a-1934-9191 | PMID 36393883 Get It

AbstractHospitals, payors, and patients increasingly expect us to report our outcomes in more detail and to justify our treatment decisions and costs. Although there are many stakeholders in surgical outcomes, physicians must take the lead role in defining how outcomes are assessed. Skull base lesions interact with surrounding anatomy to produce a complex spectrum of presentations and surgical challenges, requiring a wide variety of surgical approaches. Moreover, many skull base lesions are relatively rare. These factors and others often preclude the use of prospective randomized clinical trials, thus necessitating alternate methods of scientific inquiry. In this paper, we propose a roadmap for implementing a skull base registry, along with expected benefits and challenges.